A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).

Trial Details

NCT ID
NCT06417814
Phase
PHASE3
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Dato-DXd
  • Osimertinib
  • Pemetrexed
  • Carboplatin
  • Cisplatin
Locations (sample)
  • Fayetteville, Arkansas, United States|36.06258,-94.15743
  • Duarte, California, United States|34.13945,-117.97729
  • Fountain Valley, California, United States|33.70918,-117.95367
  • La Jolla, California, United States|32.84727,-117.2742
  • Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

  • Histologically or cytologically confirmed non-squamous NSCLC.
  • Must have evidence of documented pre-existing EGFRm information (EGFRm known to be associated with (epidermal growth factor receptor \[EGFR\] tyros…
  • Documented extra-cranial radiologic progression on prior osimertinib monotherapy (as most recent line of treatment) in the adjuvant, locally advanc…
  • Less than or equal to (\<=2) prior lines of EGFR TKIs (osimertinib is the only permitted prior third generation EGFR TKI).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →